» Articles » PMID: 3624659

Paradoxic Elevation of Fibrinopeptide A After Streptokinase: Evidence for Continued Thrombosis Despite Intense Fibrinolysis

Overview
Date 1987 Sep 1
PMID 3624659
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Elevated levels of fibrinopeptide A, a marker of thrombin activity associated with acute myocardial infarction, have been found to decrease after administration of streptokinase when reperfusion occurs. In contrast, in patients without reperfusion and those with reocclusion after streptokinase therapy, fibrinopeptide A remains elevated. In the present study early serial measurements of fibrinopeptide A were used to further characterize this paradoxic increase in thrombin activity after streptokinase and to characterize its response to heparin. In 19 patients with acute myocardial infarction fibrinopeptide A was elevated to 82.3 +/- 43.5 ng/ml (mean +/- SE) before therapy. Thirty minutes after the initiation of streptokinase, fibrinopeptide A increased to 300.1 +/- 117.4 ng/ml (p less than 0.01), consistent with extensive thrombin activity. Fibrinopeptide A remained elevated until 15 minutes after a heparin bolus injection when levels decreased to 15% of the poststreptokinase value (49.2 +/- 13.3 ng/ml) (p less than 0.001). These data document a prompt paradoxic increase in thrombin activity after administration of streptokinase that may be responsible for failure of therapy in some patients.

Citing Articles

An ATF6-tPA pathway in hepatocytes contributes to systemic fibrinolysis and is repressed by DACH1.

Zheng Z, Nayak L, Wang W, Yurdagul Jr A, Wang X, Cai B Blood. 2018; 133(7):743-753.

PMID: 30504459 PMC: 6376283. DOI: 10.1182/blood-2018-07-864843.


Amino-Terminal Fusion of Epidermal Growth Factor 4,5,6 Domains of Human Thrombomodulin on Streptokinase Confers Anti-Reocclusion Characteristics along with Plasmin-Mediated Clot Specificity.

Maheshwari N, Kantipudi S, Maheshwari A, Arora K, Vandana , Kwatra N PLoS One. 2016; 11(3):e0150315.

PMID: 26974970 PMC: 4790962. DOI: 10.1371/journal.pone.0150315.


Specific types of activated Factor XII increase following thrombolytic therapy with tenecteplase.

Ponitz V, Pritchard D, Grundt H, Nilsen D J Thromb Thrombolysis. 2006; 22(3):199-203.

PMID: 17111198 DOI: 10.1007/s11239-006-9031-6.


Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Golino P, Willerson J Tex Heart Inst J. 1991; 18(1):50-61.

PMID: 15227508 PMC: 324960.


Combination of a direct thrombin inhibitor and a platelet glycoprotein IIb/IIIa blocking peptide facilitates and maintains reperfusion of platelet-rich thrombus with alteplase.

Sabatine M, Tu T, Jang I J Thromb Thrombolysis. 2000; 10(2):189-96.

PMID: 11005941 DOI: 10.1023/a:1018722828543.